Exact Sciences(US:EXAS)2025-05-01 22:49Financial Performance - Total revenue in 1Q25 reached $707 million, an 11% year-over-year increase[5] - Core revenue also grew by 11% in 1Q25[7] - Screening revenue increased by 14% from $475 million in 1Q24 to $540 million in 1Q25[8] - Precision Oncology core revenue increased by 4% from $161 million in 1Q24 to $167 million in 1Q25[8] - Adjusted EBITDA increased by $24 million, from $39 million in 1Q24 to $63 million in 1Q25[11] - Adjusted EBITDA margin improved by 280 basis points, from 6% in 1Q24 to 9% in 1Q25[11] Updated 2025 Guidance - Total revenue guidance updated to $3.070 - $3.120 billion, an increase of $40 million at the midpoint[13] - Screening revenue guidance updated to $2.390 - $2.425 billion, an increase of $38 million at the midpoint[13] - Precision Oncology revenue guidance updated to $680 - $695 million, an increase of $3 million at the midpoint[13] - Adjusted EBITDA guidance updated to $425 - $455 million, an increase of $15 million at the midpoint[13] Product Development and Commercial Progress - Customer engagement increased by approximately 30% year-over-year[16] - The number of ordering providers in 1Q25 exceeded 190,000, representing nearly a 10% year-over-year increase[17] - The company is making progress with multi-cancer early detection and upcoming milestones[20, 27, 30]